Advanced search

Online first
Review Article
Published online: 2024-06-27

open access

View PDF Download PDF file
Supp./Additional Files
Page views 102
Article views/downloads 62
Get Citation

Connect on Social Media

Connect on Social Media

Indomethacin-responsive trigeminal autonomic cephalgias: a review of key characteristics and pathophysiology

Aleksander Osiowski1, Kacper Stolarz1, Katarzyna Baran2, Maksymilian Osiowski1, Tomasz Klepinowski3, Dominik Taterra14
DOI: 10.5603/pjnns.99747
Pubmed: 38935422

Abstract

Trigeminal autonomic cephalgias (TACs) are a well-defined subset of uncommon primary headaches that share comparable onset, pathophysiology and symptom patterns. TACs are characterised by the presentation of one-sided and high-intensity trigeminal pain together with unilateral cranial autonomic signs, which can include lacrimation, rhinorrhea, and miosis. The International Classification of Headache Disorders 3rd Edition recognises four different headache entities in this group, with cluster headache as the most recognised among them. Hemicrania continua (HC) and paroxysmal hemicrania (PH) are both distinctive cephalgias of which the diagnostic criteria include an absolute response to indomethacin. Consequently, for this reason they are often referred to as ‘indomethacin-responsive’ TACs.

The main focus of this review was to discuss the state of knowledge regarding the pathophysiology and key characteristics of PH and HC. Given the limited understanding of these conditions, and their exceptionally uncommon prevalence, a correct diagnosis can pose a clinical challenge and the search for an effective treatment may be prolonged, which frequently has a serious impact upon patients’ quality of life. The information provided in this review is meant to help physicians to differentiate indomethacin-sensitive cephalgias from other distinct headache disorders with a relatively similar clinical presentation, such as cluster headache, trigeminal neuralgia, and various migraine conditions.

Keywords: trigeminal-autonomic cephalgiasSjaastad syndromeindomethacinhemicrania continuaparoxysmal hemicrania

Article available in PDF format

View PDF Download PDF file

References

  1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1): 1–211.
    CrossRefPubMed
  2. Vincent MB. Hemicrania continua. Unquestionably a trigeminal autonomic cephalalgia. Headache. 2013; 53(5): 863–868.
    CrossRefPubMed
  3. Matharu MS, Cohen AS, McGonigle DJ, et al. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache. 2004; 44(8): 747–761.
    CrossRefPubMed
  4. Sjaastad O, Bakketeig LS. Cluster headache prevalence. Vågå study of headache epidemiology. Cephalalgia. 2003; 23(7): 528–533.
    CrossRefPubMed
  5. Sandkuhler J., Inhibitation and faciliation of nociception. https://books.google.com/books?hl=pl&lr=&id=F5VMlANd9iYC&oi=fnd&pg=PA111&ots=riOTpG9el2&sig=F5TheliAfVVgwp2mSbJvIG6hOfk (11.11.2023).
  6. Boes CJ, Dodick DW. Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patients. Headache. 2002; 42(8): 699–708.
    CrossRefPubMed
  7. Cittadini E, Matharu MS, Goadsby PJ. Paroxysmal hemicrania: a prospective clinical study of 31 cases. Brain. 2008; 131(Pt 4): 1142–1155.
    CrossRefPubMed
  8. Al-Khazali HM, Al-Khazali S, Iljazi A, et al. Prevalence and clinical features of hemicrania continua in clinic-based studies: A systematic review and meta-analysis. Cephalalgia. 2023; 43(1): 3331024221131343.
    CrossRefPubMed
  9. Costa A, Antonaci F, Ramusino MC, et al. The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias. Curr Neuropharmacol. 2015; 13(3): 304–323.
    CrossRefPubMed
  10. Viana M, Tassorelli C, Allena M, et al. Diagnostic and therapeutic errors in trigeminal autonomic cephalalgias and hemicrania continua: a systematic review. J Headache Pain. 2013; 14(1): 14.
    CrossRefPubMed
  11. May A. Diagnosis and clinical features of trigemino-autonomic headaches. Headache. 2013; 53(9): 1470–1478.
    CrossRefPubMed
  12. Castellsague J, Riera-Guardia N, Calingaert B, et al. Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012; 35(12): 1127–1146.
    CrossRefPubMed
  13. Sjaastad O, Dale I. Headache: The Journal of Head and Face Pain. 1974; 14(2): 105–108.
    CrossRefPubMed
  14. Kudrow L, Esperanca P, Vijayan N. Episodic paroxysmal hemicrania? Cephalalgia. 1987; 7(3): 197–201.
    CrossRefPubMed
  15. Veloso GG, Kaup AO, Peres MF, et al. Episodic paroxysmal hemicrania with seasonal variation: case report and the EPH-cluster headache continuum hypothesis. Arq Neuropsiquiatr. 2001; 59(4): 944–947.
    CrossRefPubMed
  16. Sjaastad O. Paroxysmal hemicrania. Neurology. 1993; 43(7): 1445–1447.
    CrossRefPubMed
  17. Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain. 1997; 120((Pt 1)): 193–209.
    CrossRefPubMed
  18. Pareja JA, Caminero AB, Franco E, et al. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua. Cephalalgia. 2001; 21(9): 906–910.
    CrossRefPubMed
  19. Henningsen MJ, Larsen JG, Karlsson WK, et al. Epidemiology and clinical features of paroxysmal hemicrania: A systematic review and meta-analysis. Headache. 2024; 64(1): 5–15.
    CrossRefPubMed
  20. Eller M, Goadsby PJ. Trigeminal autonomic cephalalgias. Oral Dis. 2016; 22(1): 1–8.
    CrossRefPubMed
  21. Irimia P, Cittadini E, Paemeleire K, et al. Unilateral photophobia or phonophobia in migraine compared with trigeminal autonomic cephalalgias. Cephalalgia. 2008; 28(6): 626–630.
    CrossRefPubMed
  22. Medina JL, Diamond S. Cluster headache variant. Spectrum of a new headache syndrome. Arch Neurol. 1981; 38(11): 705–709.
    CrossRefPubMed
  23. Sjaastad O, Spierings EL. "Hemicrania continua": another headache absolutely responsive to indomethacin. Cephalalgia. 1984; 4(1): 65–70.
    CrossRefPubMed
  24. Antonaci F, Sjaastad O. "Hemicrania continua": a clinical review. Headache. 2020; 97: 483–487.
    CrossRefPubMed
  25. Prakash S, Patel P. Hemicrania continua: clinical review, diagnosis and management. J Pain Res. 2017; 10: 1493–1509.
    CrossRefPubMed
  26. Dodick DW. Migraine. Lancet. 2018; 391(10127): 1315–1330.
    CrossRefPubMed
  27. Espada F, Morales-Asín F, Escalza I, et al. Hemicrania continua: nine new cases. Cephalgia. 1999; 19: 442–444.
  28. Peres MFP. Hemicrania continua: recent treatment strategies and diagnostic evaluation. Curr Neurol Neurosci Rep. 2002; 2(2): 108–113.
    CrossRefPubMed
  29. Peres MF, Silberstein SD, Nahmias S, et al. Hemicrania continua is not that rare. Neurology. 2001; 57(6): 948–951.
    CrossRefPubMed
  30. Rossi P, Faroni J, Tassorelli C, et al. Diagnostic delay and suboptimal management in a referral population with hemicrania continua. Headache. 2009; 49(2): 227–234.
    CrossRefPubMed
  31. Osman C, Bahra A. Paroxysmal Hemicrania. Ann Indian Acad Neurol. 2018; 21(Suppl 1): S16–S22.
    CrossRefPubMed
  32. de Almeida DB, Cunali PA, Santos HL, et al. Chronic paroxysmal hemicrania in early childhood: case report. Cephalalgia. 2004; 24(7): 608–609.
    CrossRefPubMed
  33. Guerrero ÁL, Herrero-Velázquez S, Peñas ML, et al. Peripheral nerve blocks: a therapeutic alternative for hemicrania continua. Cephalalgia. 2012; 32(6): 505–508.
    CrossRefPubMed
  34. Antonaci F, Sjaastad O. Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations. Headache. 1989; 29(10): 648–656.
    CrossRefPubMed
  35. Cohen AS, Matharu MS, Goadsby PJ. Paroxysmal hemicrania in a family. Cephalalgia. 2006; 26(4): 486–488.
    CrossRefPubMed
  36. Weatherall MW, Bahra A. Familial hemicrania continua. Cephalalgia. 2011; 31(2): 245–249.
    CrossRefPubMed
  37. Ahmed F. Handbook of headache: Practical management. Cephalalgia. 2012; 32(16): 1230–1230.
    CrossRef
  38. Leone M, Bussone G. Pathophysiology of trigeminal autonomic cephalalgias. Lancet Neurol. 2009; 8(8): 755–764.
    CrossRefPubMed
  39. May A, Bahra A, Büchel C, et al. Hypothalamic activation in cluster headache attacks. Lancet. 1998; 352(9124): 275–278.
    CrossRefPubMed
  40. Matharu M, May A. Functional and structural neuroimaging in trigeminal autonomic cephalalgias. Curr Pain Headache Rep. 2008; 12(2): 132–137.
    CrossRefPubMed
  41. Goadsby PJ. Lacrimation, conjunctival injection, nasal symptoms... cluster headache, migraine and cranial autonomic symptoms in primary headache disorders -- what's new? J Neurol Neurosurg Psychiatry. 2009; 80(10): 1057–1058.
    CrossRefPubMed
  42. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999; 19(2): 115–127.
    CrossRefPubMed
  43. Frese A, Evers S, May A. Autonomic activation in experimental trigeminal pain. Cephalalgia. 2003; 23(1): 67–68.
    CrossRefPubMed
  44. Feindel W, Penfiels W, McNaughton F. The tentorial nerves and Iocalization of intracranial pain in man. Neurology. 1960; 10: 555–563.
    CrossRefPubMed
  45. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. J Anat. 1997; 190 ( Pt 3)(Pt 3): 367–375.
    CrossRefPubMed
  46. Knight YE, Classey JD, Lasalandra MP, et al. Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious craniovascular stimulation and periaqueductal gray stimulation in the cat. Brain Res. 2005; 1045(1-2): 1–11.
    CrossRefPubMed
  47. Goadsby PJ, Lambert GA, Lance JW, et al. Effects of locus coeruleus stimulation on carotid vascular resistance in the cat. Brain Res. 1983; 278(1-2): 175–183.
    CrossRefPubMed
  48. Goadsby PJ, Lambert GA, Lance JW. The peripheral pathway for extracranial vasodilatation in the cat. J Auton Nerv Syst. 1984; 10(2): 145–155.
    CrossRefPubMed
  49. Goadsby PJ, MacDonald GJ. Extracranial vasodilation mediated by vasoactive intestinal polypeptide (VIP). Brain Res. 1985; 329(1-2): 285–288.
    CrossRefPubMed
  50. Barloese MCJ. The pathophysiology of the trigeminal autonomic cephalalgias, with clinical implications. Clin Auton Res. 2018; 28(3): 315–324.
    CrossRefPubMed
  51. Drummond PD, Drummond PD, Drummond PD. Autonomic disturbances in cluster headache. Brain. 1988; 111 ( Pt 5)(8): 1199–1209.
    CrossRefPubMed
  52. Goadsby PJ, Edvinsson L. Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache. 1994; 34(7): 394–399.
    CrossRefPubMed
  53. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994; 117 ( Pt 3): 427–434.
    CrossRefPubMed
  54. Goadsby PJ, Edvinsson L. Neuropeptide changes in a case of chronic paroxysmal hemicrania--evidence for trigemino-parasympathetic activation. Cephalalgia. 1996; 16(6): 448–450.
    CrossRefPubMed
  55. Malick A, Burstein R. Cells of origin of the trigeminohypothalamic tract in the rat. J Comp Neurol. 1998; 400(1): 125–144, doi: 10.1002/(sici)1096-9861(19981012)400:1<125::aid-cne9>3.0.co;2-b.
    PubMed
  56. Malick A, Strassman RM, Burstein R. Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat. J Neurophysiol. 2000; 84(4): 2078–2112.
    CrossRefPubMed
  57. Depaulis A, Bandler R. The midbrain periaqueductal gray matter : functional, anatomical, and neurochemical organization. NATO Science Series A: (NSSA, volume 213) 1991: 473.
  58. Boes CJ, Swanson JW, Dodick DW. Chronic paroxysmal hemicrania presenting as otalgia with a sensation of external acoustic meatus obstruction: two cases and a pathophysiologic hypothesis. Headache. 1998; 38(10): 787–791.
    CrossRefPubMed
  59. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache. 1987; 27(8): 416–420.
    CrossRefPubMed
  60. Gatzonis S, Mitsikostas DD, Ilias A, et al. Two more secondary headaches mimicking chronic paroxysmal hemicrania. Is this the exception or the rule? Headache. 1996; 36(8): 511–513.
    CrossRefPubMed
  61. Prakash S, Shah ND, Soni RK. Secondary hemicrania continua: Case reports and a literature review. J Neurol Sci. 2009; 280(1-2): 29–34.
    CrossRefPubMed
  62. Brilla R, Pawlowski M, Evers S. Hemicrania continua in carotid artery dissection - symptomatic cases or linked pathophysiology? Cephalalgia. 2018; 38(2): 402–405.
    CrossRefPubMed
  63. Mathew T, Badachi S, Sarma GRK, et al. Cerebral venous thrombosis masquerading as hemicrania continua. Neurol India. 2014; 62(5): 556–557.
    CrossRefPubMed
  64. Wang SJ, Hung CW, Fuh JL, et al. Cranial autonomic symptoms in patients with pituitary adenoma presenting with headaches. Acta Neurol Taiwan. 2009; 18(2): 104–112.
    PubMed
  65. Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain. 2010; 133(Pt 7): 1973–1986.
    CrossRefPubMed
  66. Mainardi F, Zanchin G, Maggioni F. Hemicrania Continua-Like Headache Related to Transdermal Nitroglycerine Therapy. Headache. 2017; 57(3): 494–496.
    CrossRefPubMed
  67. Prakash S, Golwala P. A proposal for revision of hemicrania continua diagnostic criteria based on critical analysis of 62 patients. Cephalalgia. 2012; 32(11): 860–868.
    CrossRefPubMed
  68. Zhang Y, Wang D, He Z, et al. Hemicrania continua-like headache secondary to nasopharyngeal carcinoma: A case report. Cephalalgia. 2017; 37(10): 1005–1007.
    CrossRefPubMed
  69. DeLange JM, Robertson CE, Krecke KN, et al. A case report of hemicrania continua-like headache due to ipsilateral inflammatory orbital pseudotumor. Headache. 2014; 54(9): 1541–1542.
    CrossRefPubMed
  70. Prakash S, Dholakia SY. Hemicrania continua-like headache with leprosy: casual or causal association? Headache. 2008; 48(7): 1132–1134.
    CrossRefPubMed
  71. Ferreira 1 KS, Freitas DJ, Speciali JG. Is there a relation between hemicrania continua and leprosy. Indian J Lepr . 2012; 84(4): 317–320.
    PubMed
  72. Eross EJ, Swanson JW, Dodick DW. Hemicrania continua: an indomethacin-responsive case with an underlying malignant etiology. Headache. 2002; 42(6): 527–529.
    CrossRefPubMed
  73. Evans RW. Hemicrania Continua-like headache due to nonmetastatic lung cancer--a vagal cephalalgia. Headache. 2007; 47(9): 1349–1351.
    CrossRefPubMed
  74. Robbins MS, Grosberg BM. Hemicrania continua-like headache from metastatic lung cancer. Headache. 2010; 50(6): 1055–1056.
    CrossRefPubMed
  75. Newman LC, Broner SW, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998; 51(1): 307–309.
    CrossRefPubMed
  76. Rozen TD. How effective is melatonin as a preventive treatment for hemicrania continua? A clinic-based study. Headache. 2015; 55(3): 430–436.
    CrossRefPubMed
  77. Wheeler SD. Hemicrania continua in African Americans. J Natl Med Assoc. 2002; 94(10): 901–907.
    PubMed
  78. Schwedt TJ, Dodick DW, Trentman TL, et al. Occipital nerve stimulation for chronic cluster headache and hemicrania continua: pain relief and persistence of autonomic features. Cephalalgia. 2006; 26(8): 1025–1027.
    CrossRefPubMed
  79. Arafah BM, Prunty D, Ybarra J, et al. The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab. 2000; 85(5): 1789–1793.
    CrossRefPubMed
  80. Levy MJ, Matharu MS, Meeran K, et al. The clinical characteristics of headache in patients with pituitary tumours. Brain. 2005; 128(Pt 8): 1921–1930.
    CrossRefPubMed
  81. Wilbrink LA, Ferrari MD, Kruit MC, et al. Neuroimaging in trigeminal autonomic cephalgias: when, how, and of what? Curr Opin Neurol. 2009; 22(3): 247–253.
    CrossRefPubMed
  82. Tabata H, Kitaguchi H. Hemicrania Continua Subsequent to Vertebral Artery Dissection: A Case Report. J Stroke Cerebrovasc Dis. 2019; 28(12): 104443.
    CrossRefPubMed
  83. Ekbom K. Nitrolglycerin as a provocative agent in cluster headache. Arch Neurol. 1968; 19(5): 487–493.
    CrossRefPubMed
  84. Pareja J, Sjaastad O. SUNCT Syndrome. A Clinical Review. Headache: The Journal of Head and Face Pain. 1997; 37(4): 195–202.
    CrossRefPubMed
  85. Lucas S. The Pharmacology of Indomethacin. Headache: The Journal of Head and Face Pain. 2016; 56(2): 436–446.
    CrossRefPubMed
  86. Tolman EL, Rosenthale ME, Capetola RJ, et al. Suprofen: the pharmacology and clinical efficacy of a new non-narcotic peripheral analgesic. Clin Rheum Dis. 1984; 10(2): 353–368.
    PubMed
  87. Matharu MS, Bradbury P, Swash M. Hemicrania continua: side alternation and response to topiramate. Cephalalgia. 2006; 26(3): 341–344.
    CrossRefPubMed
  88. Summ O, Andreou AP, Akerman S, et al. A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches. J Headache Pain. 2010; 11(6): 477–483.
    CrossRefPubMed
  89. Vincent MB. Cyclooxygenase inhibitors modify the relaxant effect of vasoactive intestinal polypeptide and substance P in isolated porcine ophthalmic artery. Cephalalgia. 1992; 12(1): 15–19.
    CrossRefPubMed
  90. Goadsby PJ, Uddman R, Edvinsson L. Cerebral vasodilatation in the cat involves nitric oxide from parasympathetic nerves. Brain Res. 1996; 707(1): 110–118.
    CrossRefPubMed
  91. Summ O, Andreou AP, Akerman S, et al. Differential actions of indomethacin: clinical relevance in headache. Pain. 2021; 162(2): 591–599.
    CrossRefPubMed
  92. Beasley TC, Bari F, Thore C, et al. Cerebral ischemia/reperfusion increases endothelial nitric oxide synthase levels by an indomethacin-sensitive mechanism. J Cereb Blood Flow Metab. 1998; 18(1): 88–96.
    CrossRefPubMed
  93. Hrabák A, Vercruysse V, Kahán IL, et al. Indomethacin prevents the induction of inducible nitric oxide synthase in murine peritoneal macrophages and decreases their nitric oxide production. Life Sci. 2001; 68(16): 1923–1930.
    CrossRefPubMed
  94. Akerman S, Holland PR, Summ O, et al. A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization. Brain. 2012; 135(Pt 12): 3664–3675.
    CrossRefPubMed
  95. Clunie M, Crone LA, Klassen L, et al. Psychiatric side effects of indomethacin in parturients. Can J Anaesth. 2003; 50(6): 586–588.
    CrossRefPubMed
  96. Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med. 1991; 151(7): 1309–1313.
    PubMed
  97. Jürgens TP, Schulte LH, May A. Indomethacin-induced de novo headache in hemicrania continua--fighting fire with fire? Cephalalgia. 2013; 33(14): 1203–1205.
    CrossRefPubMed
  98. Young T, Hollingworth M, Hollingworth M, et al. Melatonin responsive hemicrania continua in which indomethacin was associated with contralateral headache. Headache. 2014; 54(5): 916–919.
    CrossRefPubMed
  99. Dougherty C. Indomethacin-Induced Headache: Causing the Problem You Are Trying to Solve. Curr Pain Headache Rep. 2021; 25(11): 72.
    CrossRefPubMed
  100. Goodman and Gilman’s the pharmacological basis of therapeutics, https://europepmc.org/articles/pmc1916578?pdf=render (5.11.2023).
  101. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory (12.11.2023).
  102. Gazerani P, Cairns BE. Dysautonomia in the pathogenesis of migraine. Expert Rev Neurother. 2018; 18(2): 153–165.
    CrossRefPubMed
  103. Rabner J, Caruso A, Zurakowski D, et al. Autonomic dysfunction in pediatric patients with headache: migraine versus tension-type headache. Clin Auton Res. 2016; 26(6): 455–459.
    CrossRefPubMed
  104. Shechter A, Stewart WF, Silberstein SD, et al. Migraine and autonomic nervous system function: a population-based, case-control study. Neurology. 2002; 58(3): 422–427.
    CrossRefPubMed
  105. Yerdelen D, Acil T, Goksel B, et al. Heart rate recovery in migraine and tension-type headache. Headache. 2008; 48(2): 221–225.
    CrossRefPubMed
  106. Gevirtz R. The Role of the Autonomic Nervous System in Headache: Biomarkers and Treatment. Curr Pain Headache Rep. 2022; 26(10): 767–774.
    CrossRefPubMed
  107. Koenig J, Williams DP, Kemp AH, et al. Vagally mediated heart rate variability in headache patients--a systematic review and meta-analysis. Cephalalgia. 2016; 36(3): 265–278.
    CrossRefPubMed
  108. Zhang L, Qiu S, Zhao C, et al. Heart Rate Variability Analysis in Episodic Migraine: A Cross-Sectional Study. Front Neurol. 2021; 12: 647092.
    CrossRefPubMed
  109. Nicpoń KJ, Nicpoń KW, Jaroszuk-Nicpoń J. Prophylaxis of hemicrania continua: three cases effectively treated with acemethacin. Cephalalgia. 2011; 31(5): 625–627.
    CrossRefPubMed
  110. Kikui S, Sugiyama H, Miyahara J, et al. [Acemetacin, a Prodrug of Indomethacin, Is Effective for Treatment of Hemicrania Continua: A Japanese Case Report]. Brain Nerve. 2022; 74(10): 1215–1219.
    CrossRefPubMed
  111. Sjaastad O, Antonaci F. A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua. Headache. 1995; 35(9): 549–550.
    CrossRefPubMed
  112. Moura LM, Bezerra JM, Fleming NR. Treatment of hemicrania continua: case series and literature review. Rev Bras Anestesiol. 2012; 62(2): 173–187.
    CrossRefPubMed
  113. Farag M, Bahra A. Etoricoxib and celecoxib sensitive indomethacin-responsive headache disorders. Headache. 2022; 62(3): 383–388.
    CrossRefPubMed
  114. Camarda C, Camarda R, Monastero R. Chronic paroxysmal hemicrania and hemicrania continua responding to topiramate: two case reports. Clin Neurol Neurosurg. 2008; 110(1): 88–91.
    CrossRefPubMed
  115. Spears RC. Is gabapentin an effective treatment choice for hemicrania continua? J Headache Pain. 2009; 10(4): 271–275.
    CrossRefPubMed
  116. Kamourieh S, Lagrata S, Matharu MS. Non-invasive vagus nerve stimulation is beneficial in chronic paroxysmal hemicrania. J Neurol Neurosurg Psychiatry. 2019; 90(9): 1072–1074.
    CrossRefPubMed
  117. Irimia P, Arbizu J, Prieto E, et al. Activation of the brainstem but not of the hypothalamus in hemicrania continua without autonomic symptoms. Cephalalgia. 2009; 29(9): 974–979.
    CrossRefPubMed
  118. Cortijo E, Guerrero AL, Herrero S, et al. Hemicrania continua in a headache clinic: referral source and diagnostic delay in a series of 22 patients. J Headache Pain. 2012; 13(7): 567–569.
    CrossRefPubMed
  119. Rozen T. Melatonin Responsive Hemicrania Continua. Headache: The Journal of Head and Face Pain. 2006; 46(7): 1203–1204.
    CrossRefPubMed
  120. Cheung SN, Oliveira R, Goadsby PJ. Melatonin in hemicrania continua and paroxysmal hemicrania. Cephalalgia. 2024; 44(3): 3331024231226196.
    CrossRefPubMed
  121. Goadsby PJ, Dodick DW, Leone M, et al. Trial of Galcanezumab in Prevention of Episodic Cluster Headache. N Engl J Med. 2019; 381(2): 132–141.
    CrossRefPubMed
  122. González-Quintanilla V, Pérez-Pereda S, Fontanillas N, et al. First case of hemicrania continua responsive to galcanezumab. Neurol Sci. 2021; 42(11): 4775–4776.
    CrossRefPubMed
  123. Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets. 2020; 24(2): 91–100.
    CrossRefPubMed
  124. Al-Hassany L, Boucherie DM, Creeney H, et al. European Headache Federation School of Advanced Studies (EHF-SAS). Future targets for migraine treatment beyond CGRP. J Headache Pain. 2023; 24(1): 76.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Neurologia i Neurochirurgia Polska

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice